Cytotoxic T cell and neutralizing antibody responses to human immunodeficiency virus type 1 envelope with a combination vaccine regimen

Journal of Infectious Diseases

Volumn 177, Issue 2, 1998, Pages 301-309

  Corey, Lawrence ^a   McElrath, M Juliana ^a   Weinhold, Kent ^a   Matthews, Thomas ^a   Stablein, Donald ^a   Graham, Barney ^a   Keefer, Michael ^a   Schwartz, David ^a   Gorse, Geoffrey ^a  

^a NONE

Author keywords

[No Author keywords available]

Indexed keywords

BLOCKING ANTIBODY; CD4 ANTIGEN; CD8 ANTIGEN; GLYCOPROTEIN GP 120; GLYCOPROTEIN GP 160; HUMAN IMMUNODEFICIENCY VIRUS VACCINE; NEUTRALIZING ANTIBODY; RECOMBINANT PROTEIN; SMALLPOX VACCINE;

ADULT; ANTIBODY RESPONSE; ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; CYTOTOXIC T LYMPHOCYTE; DOUBLE BLIND PROCEDURE; FEMALE; HUMAN; HUMAN CELL; HUMAN EXPERIMENT; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; MALE; MULTICENTER STUDY; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; T LYMPHOCYTE SUBPOPULATION; VIRUS ENVELOPE; VIRUS NEUTRALIZATION; VIRUS TRANSMISSION;

EID: 17344365609     PISSN: 00221899     EISSN: None     Source Type: Journal    
DOI: 10.1086/514202     Document Type: Article

References (18)

1. Levy JA. Pathogenesis of human immunodeficiency virus infection. Microbiol Rev 1993;57:183-9.
2. Gadjusek DC, Amyx HL, Gibbs CJ Jr, et al. Transmission experiments with human T-lymphotropic retroviruses and human AIDS tissue. Lancet 1984;1:1415-6.
3. Haynes BF, Pantaleo G, Fauci AS. Toward an understanding of the correlates of protective immunity to HIV infection. Science 1996;271:324-8.
4. Letvin NL. Vaccines against human immunodeficiency virus, progress and prospects. N Engl J Med 1993;329:1400-5.
5. Graham BS, Wright PF. Candidate AIDS vaccines. N Engl J Med 1995;333:1331-9.
6. Hoth DF, Bolognesi DP, Corey L, Vermund SH. HIV vaccine development: a progress report. Ann Intern Med 1994;8:603-11.
7. Emini EA, Schleif WA, Nunberg JH, et al. Prevention of HIV-1 infection in chimpanzees by gp120 V3 domain-specific monoclonal antibody. Nature 1992;355:728-30.
8. Cooney EL, Collier AC, Greenberg PD, et al. Safety of and immunological response to a recombinant vaccinia virus vaccine expressing HIV envelope glycoprotein. Lancet 1991;337:567-72.
9. Mosier DE, Gulizia RJ, MacIsaac PD, Corey L, Greenberg PD. Resistance to human immunodeficiency virus 1 infection of SCID mice reconstituted with peripheral blood leukocytes from donors vaccinated with vaccinia gp160 and recombinant gp160. Proc Natl Acad Sci USA 1993;90:2443-7.
10. Cooney EL, McElrath MJ, Corey L, et al. Enhanced immunity to HIV envelope elicited by a combined vaccine regimen consisting of priming with a vaccinia recombinant expressing HIV envelope and boosting with gp160 protein. Proc Natl Acad Sci USA 1993;90:1882-6.
11. + ctytotoxic T lymphocytes. Science 1991;252:440-3.
12. + cytolytic T lymphocytes isolated from seronegative humans immunized with candidate HIV-1 vaccines. J Exp Med 1992;176:1531-42.
13. McElrath MJ, Corey L, Berger D, et al. Immune responses elicited by recombinant vaccinia-human immunodeficiency virus (HIV) envelope and HIV envelope protein: analysis of the durability of responses and effect of repeated boosting. J Infect Dis 1994;169:41-7.
14. Graham BS, Belshe RB, Clements ML, et al. Vaccination of vaccinia-naive adults with human immunodeficiency virus type 1 gp160 recombinant vaccinia virus in a blinded, controlled, randomized clinical trial. J Infect Dis 1992;166:244-52.
15. Graham BS, Matthews TJ, Belshe RB, et al. Augmentation of human immunodeficiency virus type 1 neutralizing antibody by priming with gp160 recombinant vaccinia and boosting with rgp160 in vaccinia-naive adults. J Infect Dis 1993;167:533-7.
16. + cytolytic T cells specific for HIV-infected cells by a gp160 subunit vaccine. Science 1990;248:1234-7.
17. Stanhope PE, Clements ML, Siliciano RF. Human CD4 cytolytic T lymphocyte responses to a human immunodeficiency virus type 1 gp160 subunit vaccine. J Infect Dis 1993;168:92-100.
18. Kovacs JA, Vasudevachari MB, Easter M, et al. Induction of humoral and cell-mediated anti-HIV responses in HIV seronegative volunteers by immunization with recombinant gp160. J Clin Invest 1993;92:919-28.